- Home
- DLPN vs HOOK Comparison
DLPN vs HOOK Comparison
Compare DLPN & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLPN
- HOOK
- Stock Information
- Founded
- DLPN 1996
- HOOK 2011
- Country
- DLPN United States
- HOOK United States
- Employees
- DLPN N/A
- HOOK N/A
- Industry
- DLPN Other Consumer Services
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- DLPN Consumer Discretionary
- HOOK Health Care
- Exchange
- DLPN Nasdaq
- HOOK Nasdaq
- Market Cap
- DLPN 11.4M
- HOOK 9.3M
- IPO Year
- DLPN N/A
- HOOK 2019
- Fundamental
- Price
- DLPN $1.09
- HOOK $1.30
- Analyst Decision
- DLPN Strong Buy
- HOOK Buy
- Analyst Count
- DLPN 1
- HOOK 4
- Target Price
- DLPN $5.00
- HOOK $10.67
- AVG Volume (30 Days)
- DLPN 12.9K
- HOOK 140.0K
- Earning Date
- DLPN 05-20-2025
- HOOK 05-20-2025
- Dividend Yield
- DLPN N/A
- HOOK N/A
- EPS Growth
- DLPN N/A
- HOOK N/A
- EPS
- DLPN N/A
- HOOK N/A
- Revenue
- DLPN $51,684,984.00
- HOOK $43,946,000.00
- Revenue This Year
- DLPN $2.62
- HOOK N/A
- Revenue Next Year
- DLPN $22.65
- HOOK N/A
- P/E Ratio
- DLPN N/A
- HOOK N/A
- Revenue Growth
- DLPN 19.86
- HOOK 118.32
- 52 Week Low
- DLPN $0.75
- HOOK $0.72
- 52 Week High
- DLPN $2.78
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- DLPN 54.86
- HOOK 58.05
- Support Level
- DLPN $1.00
- HOOK $1.14
- Resistance Level
- DLPN $1.16
- HOOK $1.67
- Average True Range (ATR)
- DLPN 0.06
- HOOK 0.17
- MACD
- DLPN 0.00
- HOOK 0.08
- Stochastic Oscillator
- DLPN 58.76
- HOOK 60.11
About DLPN Dolphin Entertainment Inc.
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.